Business
MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress
Topline results from Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected in the second half of 2026Topline results from Phase 2 VISTA trial of ML-007C-MA for Alzheimer’s disease psychosis expected in the second half of 2027Raised $296.5 million in gross proceeds from initial public offering and concurrent private placement completed in October 2025Cash, cash equivalents and short-term investments sufficient to fund operations through 2027 SAN FRANCISCO and BOSTON, Dec. 04, 2025 (GLOBE
About this update from Maplight Therapeutics, Inc.
[{"type":"image","alt":"MapLight Therapeutics, Inc.","displaySize":"","headline":null,"caption":"MapLight Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":54,"url":"https://media.zenfs.com/en/globenewswire.com/941d8d85f6b637b4194ef76437eebab4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/4H.ijOyaLLSu8RB2vL9Vrw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc2O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/941d8d85f6b637b4194ef76437eebab4","width":300,"height":54}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Topline results from Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected in the second half of 2026","length":109,"tagName":"p"}]},{"val":[{"type":"text","content":"Topline results from Phase 2 VISTA trial of ML-007C-MA for Alzheimer’s disease psychosis expected in the second half of 2027","length":124,"tagName":"p"}]},{"val":[{"type":"text","content":"Raised $296.5 million in gross proceeds from initial public offering and concurrent private placement completed in October 2025","length":127,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash, cash equivalents and short-term investments sufficient to fund operations through 2027","length":92,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":452,"olType":false},{"type":"text","content":"SAN FRANCISCO and BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, today reported financial results for the third quarter of 2025 and highlighted recent progress and upcoming milestones.","length":371,"tagName":"p"},{"type":"text","content":"“2025 was a year of exceptional execution and acceleration for MapLight,” said Chris Kroeger, Chief Executive Officer of MapLight Therapeutics. “In the last year, we have made noteworthy progress across our entire product candidate portfolio, including the initiation of the Phase 2 ZEPHYR and VISTA studies for ML-007C-MA, completion of enrollment in our Phase 2 IRIS study of ML-004 and advancement of our preclinical programs. With a strengthened balance sheet following our recent public offering, we are in a strong financial position to continue this momentum to advance our broad and dive...